Advertisement

Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 600x60px
Document › Details

Noxxon Pharma N.V.. (1/6/17). "Press Release: Half-yearly Report on the Liquidity Contract with Invest Securities". Berlin.

Organisations Organisation Noxxon Pharma N.V. (Alternext Paris: ALNOX)
  Group Noxxon (Group)
  Organisation 2 Invest Securities S.A.
Products Product Spiegelmer® technology
  Product 2 financial services
     


Pursuant to the liquidity contract entrusted to Invest Securities by NOXXON PHARMA (Alternext Paris: ALNOX), on 31 December 2016 the following assets appeared on the liquidity account:

> Number of shares: 10,770
> Cash balance of the liquidity account: € 83,219.

As a reminder, at the time of the last half-yearly report on 30 June 2016, the following resources were booked to the liquidity account:

> Number of shares: 10,000
> Cash balance of the liquidity account: €100,000


About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON’s Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Keytruda® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com

   
Record changed: 2017-01-17

Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px

More documents for Noxxon (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpa




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 120x240px wptb Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px